Risk factors
Oncolytics Biotech (ONCY) risk factors
Item 1A of every Oncolytics Biotech Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors52 risks
Pelareorep remains an unapproved clinical-stage candidate, with trial design, safety, efficacy, and regulatory approval dominating risk.
Filed Mar 30, 2026